Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study-MedSci.cn

Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study

Spira, A; Lisberg, A; Sands, J; Greenberg, J; Phillips, P; Guevara, F; Tajima, N; Kawasaki, Y; Gu, J; Kobayashi, F; Yamamoto, N; Johnson, M; Meric-Bernstam, F; Yoh, K; Garon, E; Heist, R; Shimizu, T

JOURNAL OF THORACIC ONCOLOGY, 2021; 16 (3): S106

科室
- - 订阅+
  - 更多科室
工具
服务